News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neurochem, Inc. (NRMX) Shifts Focus on Alzheimer's Treatment


11/8/2007 6:29:15 AM

TORONTO, Nov 8 (Reuters) - Neurochem said on Thursday it planned to ramp up development of its key Alzheimer's disease treatment NRM-8499 and terminate European trials of its tramiprosate Alzheimer's treatment as it shifts its focus on the fight with the disease.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES